OTSUKA PHARMACEUTICAL CO., LTD.
π―π΅Japan
- Country
- π―π΅Japan
- Ownership
- Public, Subsidiary
- Established
- 1964-01-01
- Employees
- 101
- Market Cap
- -
- Website
- http://www.otsuka.co.jp
Efficacy and Safety of Subcutaneous Administration of TEV-48125 for the Preventive Treatment of Chronic Migraine
Phase 2
Completed
- Conditions
- Migraine
- Interventions
- First Posted Date
- 2017-10-05
- Last Posted Date
- 2021-06-15
- Lead Sponsor
- Otsuka Pharmaceutical Co., Ltd.
- Target Recruit Count
- 571
- Registration Number
- NCT03303079
- Locations
- π―π΅
Saitama Medical University Hospital, Iruma, Japan
A Trial of C13-CAC Breath Test in PPI Resistant GERD Patients
Phase 2
Completed
- Conditions
- Gastroesophageal Reflux Disease
- Interventions
- First Posted Date
- 2017-09-15
- Last Posted Date
- 2019-04-01
- Lead Sponsor
- Otsuka Pharmaceutical Co., Ltd.
- Target Recruit Count
- 55
- Registration Number
- NCT03284177
- Locations
- π―π΅
Osaka Saiseikai Nakatsu Hospital, Osaka, Japan
π―π΅Kawasaki Medical School Hospital, Kurashiki, Japan
π―π΅Akita University Hospital, Akita, Japan
Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics Study of Tolvaptan in Pediatric Congestive Heart Failure (CHF) Patients With Volume Overload
Phase 3
Completed
- Conditions
- Pediatric Congestive Heart Failure (CHF) Patients With Volume Overload
- Interventions
- First Posted Date
- 2017-08-21
- Last Posted Date
- 2024-08-23
- Lead Sponsor
- Otsuka Pharmaceutical Co., Ltd.
- Target Recruit Count
- 60
- Registration Number
- NCT03255226
Clinical Pharmacology Trial to Investigate the Dose of OPC-61815 Injection Equivalent to Tolvaptan 15-mg Tablet in Patients With Congestive Heart Failure
Not Applicable
Completed
- Conditions
- Congestive Heart Failure
- Interventions
- Drug: OPC-61815 injection 4mgDrug: OPC-61815 injection 8mgDrug: OPC-61815 injection 16mgDrug: OPC-61815 injection 2mg
- First Posted Date
- 2017-08-18
- Last Posted Date
- 2021-07-28
- Lead Sponsor
- Otsuka Pharmaceutical Co., Ltd.
- Target Recruit Count
- 61
- Registration Number
- NCT03254108
Post-Marketing Surveillance Study of Aripiprazole in Patients With Autism
Completed
- Conditions
- Autism
- First Posted Date
- 2017-06-07
- Last Posted Date
- 2021-09-16
- Lead Sponsor
- Otsuka Pharmaceutical Co., Ltd.
- Target Recruit Count
- 528
- Registration Number
- NCT03179787
- Locations
- π―π΅
Otsuka Pharmaceutical Co., Ltd., Tokyo, Japan
A Multicenter Trial to Investigate the Efficacy and Safety of Tolvaptan in Patients With Hyponatremia in SIADH
Phase 3
Completed
- Conditions
- Syndrome of Inappropriate Antidiuretic Hormone Secretion
- Interventions
- First Posted Date
- 2017-02-09
- Last Posted Date
- 2020-11-02
- Lead Sponsor
- Otsuka Pharmaceutical Co., Ltd.
- Target Recruit Count
- 16
- Registration Number
- NCT03048747
Phase 2 Study of OPA-15406 Ointment in Pediatric Patients With Atopic Dermatitis
- First Posted Date
- 2017-01-12
- Last Posted Date
- 2020-07-23
- Lead Sponsor
- Otsuka Pharmaceutical Co., Ltd.
- Target Recruit Count
- 73
- Registration Number
- NCT03018691
A Study of OPC-41061 Orally Disintegrating (OD) Tablets Using 2 Different Formulations and 2 Dosing Regimens in Healthy Adult Male Subjects
- First Posted Date
- 2016-12-15
- Last Posted Date
- 2021-06-28
- Lead Sponsor
- Otsuka Pharmaceutical Co., Ltd.
- Target Recruit Count
- 84
- Registration Number
- NCT02994394
Study of OPA-15406 Ointment in Patients With Atopic Dermatitis
- First Posted Date
- 2016-09-26
- Last Posted Date
- 2020-07-23
- Lead Sponsor
- Otsuka Pharmaceutical Co., Ltd.
- Target Recruit Count
- 200
- Registration Number
- NCT02914548
Evaluation Study of the Bioavailability of Brexpiprazole Orally Disintegrating Tablets in Healthy Male Subjects
- First Posted Date
- 2016-08-23
- Last Posted Date
- 2021-02-23
- Lead Sponsor
- Otsuka Pharmaceutical Co., Ltd.
- Target Recruit Count
- 18
- Registration Number
- NCT02875080
Β© Copyright 2025. All Rights Reserved by MedPath